These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 32275492)

  • 1. Targeted Protein Degradation: An Emerging Therapeutic Strategy in Cancer.
    Barghout SH
    Anticancer Agents Med Chem; 2021; 21(2):214-230. PubMed ID: 32275492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The emerging role of targeted protein degradation to treat and study cancer.
    Brodermann MH; Henderson EK; Sellar RS
    J Pathol; 2024 Aug; 263(4-5):403-417. PubMed ID: 38886898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Applications of protein ubiquitylation and deubiquitylation in drug discovery.
    Chen Y; Xue H; Jin J
    J Biol Chem; 2024 May; 300(5):107264. PubMed ID: 38582446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Breaking Bad Proteins-Discovery Approaches and the Road to Clinic for Degraders.
    Bouvier C; Lawrence R; Cavallo F; Xolalpa W; Jordan A; Hjerpe R; Rodriguez MS
    Cells; 2024 Mar; 13(7):. PubMed ID: 38607017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ubiquitination and deubiquitination in cancer: from mechanisms to novel therapeutic approaches.
    Liu F; Chen J; Li K; Li H; Zhu Y; Zhai Y; Lu B; Fan Y; Liu Z; Chen X; Jia X; Dong Z; Liu K
    Mol Cancer; 2024 Jul; 23(1):148. PubMed ID: 39048965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Protein induced proximity and targeted degradations by new degraders: concepts, developments, challenges for clinical applications].
    Reboud-Ravaux M
    Biol Aujourdhui; 2024; 218(1-2):41-54. PubMed ID: 39007776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer therapies based on targeted protein degradation - lessons learned with lenalidomide.
    Jan M; Sperling AS; Ebert BL
    Nat Rev Clin Oncol; 2021 Jul; 18(7):401-417. PubMed ID: 33654306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Redefining the Scope of Targeted Protein Degradation: Translational Opportunities in Hijacking the Autophagy-Lysosome Pathway.
    Cassidy K; Zhao H
    Biochemistry; 2023 Feb; 62(3):580-587. PubMed ID: 34569233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prey for the Proteasome: Targeted Protein Degradation-A Medicinal Chemist's Perspective.
    Luh LM; Scheib U; Juenemann K; Wortmann L; Brands M; Cromm PM
    Angew Chem Int Ed Engl; 2020 Sep; 59(36):15448-15466. PubMed ID: 32428344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PROTAC targeted protein degraders: the past is prologue.
    Békés M; Langley DR; Crews CM
    Nat Rev Drug Discov; 2022 Mar; 21(3):181-200. PubMed ID: 35042991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted protein degradation in drug development: Recent advances and future challenges.
    Song J; Hu M; Zhou J; Xie S; Li T; Li Y
    Eur J Med Chem; 2023 Dec; 261():115839. PubMed ID: 37778240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strengthening Molecular Glues: Design Strategies for Improving Thalidomide Analogs as Cereblon Effectors and Anticancer Agents.
    Nutt MJ; Stewart SG
    Drug Discov Today; 2024 Jun; 29(6):104010. PubMed ID: 38704021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging protein degradation strategies: expanding the scope to extracellular and membrane proteins.
    Lin J; Jin J; Shen Y; Zhang L; Gong G; Bian H; Chen H; Nagle DG; Wu Y; Zhang W; Luan X
    Theranostics; 2021; 11(17):8337-8349. PubMed ID: 34373745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. From Thalidomide to Rational Molecular Glue Design for Targeted Protein Degradation.
    Oleinikovas V; Gainza P; Ryckmans T; Fasching B; Thomä NH
    Annu Rev Pharmacol Toxicol; 2024 Jan; 64():291-312. PubMed ID: 37585660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PROTAC-Based Protein Degradation as a Promising Strategy for Targeted Therapy in Sarcomas.
    Mancarella C; Morrione A; Scotlandi K
    Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PROTAC: Novel degradable approach for different targets to treat breast cancer.
    Wang Z; Che S; Yu Z
    Eur J Pharm Sci; 2024 Jul; 198():106793. PubMed ID: 38740076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel approaches to targeted protein degradation technologies in drug discovery.
    Xue Y; Bolinger AA; Zhou J
    Expert Opin Drug Discov; 2023 Apr; 18(4):467-483. PubMed ID: 36895136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protacs for treatment of cancer.
    Sakamoto KM
    Pediatr Res; 2010 May; 67(5):505-8. PubMed ID: 20075761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteomic approaches advancing targeted protein degradation.
    Sathe G; Sapkota GP
    Trends Pharmacol Sci; 2023 Nov; 44(11):786-801. PubMed ID: 37778939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PROTACs in Ovarian Cancer: Current Advancements and Future Perspectives.
    Vorderbruggen M; Velázquez-Martínez CA; Natarajan A; Karpf AR
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.